✦ LIBER ✦

Genetic and environmental influences on obsessive-compulsive disorder

✍ Scribed by Jessica R. Grisham; Tracy M. Anderson; Perminder S. Sachdev

Publisher: Springer-Verlag
Year: 2008
Tongue: English
Weight: 226 KB
Volume: 258
Category: Article
ISSN: 1433-8491
DOI: 10.1007/s00406-007-0789-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Obsessive–compulsive disorder and person

Obsessive–compulsive disorder and personality disorder

✍ Albina R. Torres; Paul Moran; Paul Bebbington; Traolach Brugha; Dinesh Bhugra; J 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 98 KB

Gender in obsessive-compulsive disorder

Gender in obsessive-compulsive disorder and obsessive-compulsive spectrum disorders

✍ C. Lochner; D. J. Stein 📂 Article 📅 2001 🏛 Springer Vienna 🌐 English ⚖ 66 KB

Genetics of early-onset obsessive–compul

Genetics of early-onset obsessive–compulsive disorder

✍ Susanne Walitza; Jens R. Wendland; Edna Gruenblatt; Andreas Warnke; Thomas A. So 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 202 KB

Lifetime-comorbidity of obsessive-compul

Lifetime-comorbidity of obsessive-compulsive disorder and subclinical obsessive-compulsive disorder in northern Germany

✍ Hans Joergen Grabe; Christian Meyer; Ulfert Hapke; Hans-Juergen Rumpf; Harald Ju 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 189 KB

Obsessive–compulsive spectrum conditions

Obsessive–compulsive spectrum conditions in obsessive-compulsive disorder and other anxiety disorders

✍ Margaret A. Richter; Laura J. Summerfeldt; Martin M. Antony; Richard P. Swinson 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

Pharmacotherapy for obsessive-compulsive

Pharmacotherapy for obsessive-compulsive disorder

✍ Darin D. Dougherty; Scott L. Rauch; Michael A. Jenike 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

## Abstract Pharmacotherapeutic options for obsessive‐compulsive disorder (OCD) have expanded over the past half‐century since medications were first found to be effective for the treatment of OCD. Currently, the serotonin reuptake inhibitors (SRIs) represent the first‐line pharmacotherapy for OCD.